Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4547473
Max Phase: Preclinical
Molecular Formula: C49H61N11O10
Molecular Weight: 964.09
Molecule Type: Unknown
Associated Items:
ID: ALA4547473
Max Phase: Preclinical
Molecular Formula: C49H61N11O10
Molecular Weight: 964.09
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(CC(=O)NCCCOCCOCCOCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cn3)nc2n(C2CCCC2)c1=O
Standard InChI: InChI=1S/C49H61N11O10/c1-31-36-29-53-49(56-44(36)59(33-8-3-4-9-33)47(66)42(31)32(2)61)54-39-14-12-34(28-52-39)58-20-18-57(19-21-58)30-41(63)51-17-7-23-69-25-27-70-26-24-68-22-6-16-50-37-11-5-10-35-43(37)48(67)60(46(35)65)38-13-15-40(62)55-45(38)64/h5,10-12,14,28-29,33,38,50H,3-4,6-9,13,15-27,30H2,1-2H3,(H,51,63)(H,55,62,64)(H,52,53,54,56)
Standard InChI Key: NAENXYHPJLZWFB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 964.09 | Molecular Weight (Monoisotopic): 963.4603 | AlogP: 3.14 | #Rotatable Bonds: 23 |
Polar Surface Area: 248.62 | Molecular Species: NEUTRAL | HBA: 18 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 21 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.15 | CX Basic pKa: 6.22 | CX LogP: 1.99 | CX LogD: 1.97 |
Aromatic Rings: 4 | Heavy Atoms: 70 | QED Weighted: 0.05 | Np Likeness Score: -1.02 |
1. Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A.. (2019) Selective degradation of CDK6 by a palbociclib based PROTAC., 29 (11): [PMID:30935795] [10.1016/j.bmcl.2019.03.035] |
Source(1):